The iPLEDGE program is a risk evaluation and mitigation strategy (REMS). The Food and Drug Administration (FDA) may require a REMS to help ensure that a medication’s benefits outweigh its risks. A ...
The long-awaited modifications for the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) system for the teratogenic acne drug isotretinoin, previously scheduled to go into effect August 8, 2026, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results